|
|
News Breaks | | | | March 1, 2013 | | 09:19 EDT |  | DEPO | Depomed shares should be bought on weakness, says Roth Capital
After the FDA released documents on Depomed's Sefelsa ahead of a panel meeting on the drug, Roth Capital thinks the outcome of the panel is "a coin flip." However, the firm recommends that investors buy the stock, as it thinks that the shares undervalue the rest of the company. | |
|
News For DEPO From The Last 14 Days Check below for free stories on DEPO the last two weeks. |
|
|
| There are no results for DEPO |
|
|
|
|
|
|
